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BACKGROUND
Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro 
and efficacy in animal models of coronavirus disease 2019 (Covid-19).
METHODS
We conducted a randomized, open-label, phase 3 trial involving hospitalized pa-
tients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less 
while they were breathing ambient air, and radiologic evidence of pneumonia. 
Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir 
for either 5 days or 10 days. All patients received 200 mg of remdesivir on day 1 
and 100 mg once daily on subsequent days. The primary end point was clinical 
status on day 14, assessed on a 7-point ordinal scale.
RESULTS
In total, 397 patients underwent randomization and began treatment (200 patients 
for 5 days and 197 for 10 days). The median duration of treatment was 5 days 
(interquartile range, 5 to 5) in the 5-day group and 9 days (interquartile range, 
5 to 10) in the 10-day group. At baseline, patients randomly assigned to the 10-day 
group had significantly worse clinical status than those assigned to the 5-day 
group (P = 0.02). By day 14, a clinical improvement of 2 points or more on the 
ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 
10-day group. After adjustment for baseline clinical status, patients in the 10-day 
group had a distribution in clinical status at day 14 that was similar to that among 
patients in the 5-day group (P = 0.14). The most common adverse events were nau-
sea (9% of patients), worsening respiratory failure (8%), elevated alanine amino-
transferase level (7%), and constipation (7%).
CONCLUSIONS
In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not 
show a significant difference between a 5-day course and a 10-day course of remdesi-
vir. With no placebo control, however, the magnitude of benefit cannot be determined. 
(Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899.)
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The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has plunged large parts of the world 
into a protracted medical, social, and economic 
crisis.1-4 Coronavirus disease 2019 (Covid-19), the 
respiratory illness caused by SARS-CoV-2 infec-
tion, has caused over a quarter million deaths 
worldwide, including approximately 100,000 in 
the United States.5,6 Mortality from Covid-19 is 
particularly high among patients with coexisting 
conditions, including hypertension, diabetes, and 
cardiovascular disease, and among those who 
reach the point of requiring invasive mechanical 
ventilation.7 Safe and effective treatment options 
are needed to reduce the burden of Covid-19 
disease.8,9
Remdesivir is a prodrug of an adenosine ana-
logue with demonstrated antiviral activity against 
a broad range of RNA virus families.10-13 Remdesi-
vir has shown nanomolar in vitro activity against 
SARS-CoV-2 in human airway epithelial cells and 
clinical and virologic efficacy in a primate model 
of SARS-CoV-2.14-16 Clinical trials of remdesivir 
for the treatment of Covid-19 have used a 10-day 
course of treatment that was based on efficacy 
data in animal models of Middle East respira-
tory syndrome and supported by safety data in 
approximately 500 healthy volunteers and patients 
infected with Ebola virus.17,18 Identifying the short-
est duration of effective treatment with remdesivir 
is an urgent medical need. A shorter course of 
treatment without a loss of efficacy could reduce 
hospital stays and potential adverse events and 
could extend the limited supply of remdesivir 
available during this pandemic. In this report, we 
describe the results of an open-label, randomized, 
multicenter trial evaluating the efficacy and safe-
ty of treatment with remdesivir for 5 or 10 days 
in patients with severe Covid-19 disease.
Me thods
Patients
We enrolled hospitalized patients who were at 
least 12 years of age who had SARS-CoV-2 infec-
tion confirmed by polymerase-chain-reaction as-
say within 4 days before randomization. Eligible 
patients had radiographic evidence of pulmonary 
infiltrates and either had oxygen saturation of 
94% or less while they were breathing ambient 
air or were receiving supplemental oxygen. Patients 
who were receiving mechanical ventilation and 
extracorporeal membrane oxygenation (ECMO) 
at screening were excluded, as were patients with 
signs of multiorgan failure. Exclusion criteria in-
cluded alanine aminotransferase (ALT) or aspar-
tate aminotransferase (AST) levels greater than 
5 times the upper limit of the normal range or 
estimated creatinine clearance of less than 50 ml 
per minute (by the Cockcroft–Gault formula). Pa-
tients receiving concurrent treatment (within 24 
hours before the start of trial treatment) with 
other agents with putative activity against Covid-19 
were excluded.
Trial Design and Oversight
For this ongoing phase 3 trial, patients were en-
rolled at 55 hospitals in the United States, Italy, 
Spain, Germany, Hong Kong, Singapore, South 
Korea, and Taiwan between March 6 and March 
26, 2020. Patients were randomly assigned in a 
1:1 ratio to receive intravenous treatment with 
remdesivir for 5 days or 10 days. The randomiza-
tion was not stratified. All the patients were to 
receive 200 mg of remdesivir on day 1, followed 
by 100 mg of remdesivir once daily for the subse-
quent 4 or 9 days. Both treatment groups contin-
ued supportive therapy at the discretion of the 
investigator throughout the duration of the trial. 
The protocol (available with the full text of this 
article at NEJM.org) did not mandate that pa-
tients whose condition improved enough to war-
rant hospital discharge complete the full course 
of assigned remdesivir treatment.
The protocol was amended on March 15, 2020, 
after the beginning of enrollment but before any 
results were available. The lower age limit for 
eligibility was reduced from 18 years to 12 years, 
and a requirement for an axillary temperature of 
at least 36.6°C at screening was eliminated. In 
addition, one of the primary efficacy assessments 
— the proportions of patients with normaliza-
tion of temperature at day 14 — was changed to 
assessment of clinical status on a 7-point ordinal 
scale on day 14 (described below). This change 
was made in response to an evolving understand-
ing of the signs and symptoms of Covid-19 during 
hospitalization and in recognition of emerging 
standards for assessment of Covid-19.19,20 The 
protocol was also amended to add an extension 
phase involving an additional 5600 patients, in-
cluding a cohort of patients receiving mechanical 
ventilation (results of the extension phase are not 
reported here). All versions of the protocol and 
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summaries of the amendments are available at 
NEJM.org.
The trial was approved by the institutional 
review board or ethics committee at each site 
and was conducted in compliance with the Dec-
laration of Helsinki Good Clinical Practice guide-
lines and local regulatory requirements. The 
trial was designed and conducted by the sponsor 
(Gilead Sciences) in collaboration with the prin-
cipal investigators and in accordance with the 
protocol and amendments. The sponsor collected 
the data, monitored the conduct of the trial, and 
performed the statistical analyses. An indepen-
dent safety monitoring committee reviewed data 
on day 14 of the trial, when all the patients had 
reached the primary end point. They agreed that 
the 5-day and 10-day treatment groups had similar 
outcomes, and they unanimously recommended 
that the trial continue into the second part ac-
cording to the protocol. The authors vouch for 
the integrity and completeness of the data and 
the fidelity of the trial to the protocol. The ini-
tial draft of the manuscript was prepared by a 
writer employed by Gilead Sciences, with input 
from all the authors.
Clinical and Laboratory Monitoring
Patients were assessed by physical examination 
and by documentation of respiratory status, ad-
verse events, and concomitant medications. On 
trial days 1, 3, 5, 8, 10, and 14, blood samples 
were obtained for complete blood count and mea-
surement of creatinine, glucose, total bilirubin, 
and liver aminotransferases.
The clinical status of patients was assessed 
daily on a 7-point ordinal scale (see below) from 
day 1 through 14 or until discharge. The worst 
(i.e., the lowest) score from each day was recorded.
End Points
The primary efficacy end point was clinical sta-
tus assessed on day 14 on a 7-point ordinal scale 
consisting of the following categories: 1, death; 
2, hospitalized, receiving invasive mechanical 
ventilation or ECMO; 3, hospitalized, receiving 
noninvasive ventilation or high-flow oxygen devic-
es; 4, hospitalized, requiring low-flow supplemen-
tal oxygen; 5, hospitalized, not requiring supple-
mental oxygen but receiving ongoing medical 
care (related or not related to Covid-19); 6, hospi-
talized, requiring neither supplemental oxygen nor 
ongoing medical care (other than that specified 
in the protocol for remdesivir administration); 
and 7, not hospitalized (see Table S1 in the Sup-
plementary Appendix, available at NEJM.org).
The secondary end point of the trial was the 
proportion of patients with adverse events that 
occurred on or after the first dose of remdesivir 
for up to 30 days after the last dose. Prespecified 
exploratory end points included the time to clini-
cal improvement (defined as an improvement of 
at least 2 points from baseline on the 7-point 
ordinal scale), the time to recovery (defined by 
the National Institute of Allergy and Infectious 
Diseases [NIAID] as an improvement from a 
baseline score of 2 to 5 to a score of 6 or 7), the 
time to modified recovery (defined as an im-
provement from a baseline score of 2 to 4 to a 
score of 5 to 7 or from a score of 5 to a score of 
6 or 7), and death from any cause.
Statistical Analysis
We calculated that a sample size of 400 patients 
(200 in each group) would provide greater than 
85% power to detect an odds ratio for improve-
ment of 1.75, using a two-sided significance 
level of 0.05. All patients who were randomized 
and received at least one dose of remdesivir were 
assessed for efficacy and safety. If a patient died 
before day 14, the day 14 category on the ordinal 
scale was recorded as “died”; if a patient was 
discharged before day 14, the category was re-
corded as “not hospitalized”; otherwise, the most 
recent assessment was used for missing day 14 
values. The prespecified primary analysis, per-
formed after all patients completed 14 days in 
the trial, used the proportional odds model, in-
cluding treatment as the independent variable 
and baseline clinical status as a continuous co-
variate. The conclusion would be that 10 days of 
treatment was superior to 5 days of treatment if 
the lower bound of the two-sided 95% confidence 
interval of the odds ratio (10 days to 5 days) on 
day 14 was greater than 1. The stratified Wil-
coxon rank-sum test was prespecified to compare 
the treatment groups in case the proportional 
odds assumption was not met. For time-to-event 
end points (such as the time to clinical improve-
ment, the time to recovery, and the time to 
modified recovery), the hazard ratio and its 95% 
confidence interval were estimated from a cause-
specific proportional-hazards model that included 
treatment and baseline clinical status as covariates 
and treated death as the competing risk. For 
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events associated with prespecified times (e.g., 
days 5, 7, 11, and 14), the difference in the pro-
portion of patients with an event under evalua-
tion (such as clinical improvement, recovery, and 
modified recovery) between treatment groups and 
its 95% confidence interval were estimated from 
the Mantel–Haenszel proportions, with adjustment 
according to baseline clinical status. For end 
points other than the primary end point, 95% 
confidence intervals have not been adjusted for 




Of the 408 patients who were assessed for eligi-
bility, 402 were enrolled and underwent random-
ization and 397 began treatment: 200 patients were 
assigned to receive a 5-day course of remdesivir 
and 197 a 10-day course (Fig. 1). The treatment 
groups were balanced in demographic character-
istics but not in baseline disease characteristics 
(Table 1). Greater proportions of patients in the 
10-day group were in the two highest disease-
severity groups. In the case of 13 patients, either 
a requirement for invasive mechanical ventilation 
developed between screening and the beginning 
of treatment or the patients were designated as 
representing protocol deviations at enrollment: 
4 of these patients (2%) were assigned to a 5-day 
course of remdesivir and 9 (5%) to a 10-day course. 
High-flow oxygen support was required at baseline 
by more patients in the 10-day group than in the 
5-day group (30% vs. 24%). As a result, patients 
in the 10-day group had significantly worse clini-
cal status than those in the 5-day group (P = 0.02).
Of the 200 patients in the 5-day group, 172 
(86%) completed the course of trial treatment for 
a median duration of 5 days (interquartile range, 
5 to 5). Of those who did not complete the 5-day 
course of treatment, reasons included hospital 
discharge (16 patients [8%]) and adverse events 
(9 [4%]). No patient in the 5-day group stopped 
treatment because of death. Of the 197 patients 
in the 10-day group, 86 (44%) completed the course 
of treatment for a median duration of 9 days (in-
terquartile range, 5 to 10). Of those who did not 
complete the 10-day course, reasons included 
hospital discharge (68 patients [35%]), adverse 
events (22 [11%]), and death (12 [6%]) (for a full 
account of the disposition of patients, see Fig. 1). 
By day 14, a total of 16 patients (8%) in the 5-day 
group and 21 patients (11%) in the 10-day group 
had died, and 120 (60%) and 103 (52%), respec-
tively, had been discharged (Table 2).
Efficacy
In all, 65% of patients who received a 5-day course 
of remdesivir showed a clinical improvement of at 
least 2 points on the 7-point ordinal scale at day 14, 
as compared with 54% of patients who received 
a 10-day course (Table 2). After adjustment for 
imbalances in baseline clinical status, patients 
receiving a 10-day course of remdesivir had a 
distribution in clinical status at day 14 that was 
similar to that of patients receiving a 5-day course 
(P = 0.14 by stratified Wilcoxon rank-sum test).
For other efficacy end points of interest, the 
two groups had similar outcomes after adjust-
ment for baseline clinical status (Table 2). The 
median duration of hospitalization among pa-
tients discharged on or before day 14 was 7 days 
(interquartile range, 6 to 10) for the 5-day group 
and 8 days (interquartile range, 5 to 10) for the 
10-day group. Numerically more patients were 
discharged from the hospital in the 5-day group 
than in the 10-day group (60%, vs. 52%), and 
mortality was numerically lower (8%, vs. 11%). 
Discharge rates were higher in the overall popu-
lation among patients who had had symptoms 
for less than 10 days before receiving the first 
dose of remdesivir (62%) than among those who 
had had symptoms for 10 or more days before 
receiving the first dose (49%).
The proportions of patients who recovered — 
those with a baseline score of 2 to 5 on the ordinal 
scale who improved to a score of 6 or 7 — showed 
the same trend: 64% of patients in the 5-day 
group, as compared with 54% of patients in the 
10-day group (for a baseline-adjusted difference in 
proportions of −6.3% [95% confidence interval, 
−15.4 to 2.8]). The median time to recovery was 10 
days (interquartile range, 6 to 18) among patients 
in the 5-day group and 11 days (interquartile 
range, 7 to not possible to estimate) among pa-
tients in the 10-day group. Evaluation of modified 
recovery showed similar trends, with nonsignifi-
cant differences between treatment groups after 
adjustment for baseline clinical status.
We conducted a post hoc analysis to determine 
whether any subpopulation might have benefitted 
from receiving more than 5 days of therapy with 
remdesivir (Fig. 2). The oxygen-support status 
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among all patients still hospitalized on day 5 was 
noted. Patients were then evaluated according to 
original treatment assignment for day 14 out-
comes, to determine the effect of an additional 
5 days of treatment with remdesivir. Among pa-
tients receiving mechanical ventilation or ECMO 
at day 5, 40% (10 of 25) in the 5-day group had 
died by day 14, as compared with 17% (7 of 41) in 
the 10-day group (Fig. 2). Treatment with remdes-
ivir beyond 5 days among patients who were re-
ceiving noninvasive positive-pressure ventilation 
or high-flow oxygen, receiving low-flow oxygen, 
or breathing ambient air did not appear to im-
prove outcomes. In multivariate analysis, charac-
teristics associated with shorter time to clinical 
improvement were an age of less than 65 years, 
black and white race, a baseline oxygen require-
ment of low-flow oxygen or ambient air, no use 
of a biologic medication, and enrollment outside 
Italy (Tables S3 and S4).
Figure 1. Enrollment and Randomization.
402 Underwent randomization
408 Patients were assessed for eligibility
6 Were excluded
5 Did not meet enrollment criteria
1 Improved after screening and was eligible
for discharge
202 Were assigned to receive
a 5-day course of remdesivir
200 Were assigned to receive
a 10-day course of remdesivir
3 Were not treated
2 Underwent randomi-
zation in error
1 Was withdrawn by
investigator




200 Were included in the efficacy
and safety analyses
197 Were included in the efficacy
and safety analyses
200 Started trial treatment 197 Started trial treatment
111 Discontinued treatment
68 Were discharged
22 Had adverse event
12 Died
5 Were withdrawn by investigator
3 Withdrew
1 Had protocol violation
28 Discontinued treatment
16 Were discharged
9 Had adverse event
2 Withdrew
1 Had protocol violation
172 Completed treatment 86 Completed treatment
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Safety
The percentages of patients experiencing adverse 
events were similar in the two groups: 70% in 
the 5-day group and 74% in the 10-day group 
(Table 3). In all, 21% of patients in the 5-day group 
and 35% in the 10-day group had serious adverse 
events. Similar results were seen in the percent-
ages of patients experiencing any adverse event of 
grade 3 or higher: 30% in the 5-day group and 
43% in the 10-day group. The most common 
adverse events overall were nausea (10% in the 
5-day group vs. 9% in the 10-day group), acute 
respiratory failure (6% vs. 11%), increased ALT 
(6% vs. 8%), and constipation (7% in both groups). 
The percentage of patients who discontinued 
treatment owing to adverse events was 4% in the 
5-day group, as compared with 10% in the 10-day 
group.
In an exploratory analysis of the first 5 days of 
therapy, rates of adverse events differed between 







Median age (IQR) — yr 61 (50–69) 62 (50–71)
Male sex — no. (%) 120 (60) 133 (68)
Race — no./total no. (%)†
White 142/200 (71) 134/192 (70)
Black 21/200 (10) 23/192 (12)
Asian 20/200 (10) 25/192 (13)
Other 17/200 (8) 10/192 (5)
Median body-mass index (IQR)‡ 29 (25–34) 29 (25–33)
Coexisting conditions of interest — no. (%)
Diabetes  47 (24)  43 (22)
Hyperlipidemia  40 (20)  49 (25)
Hypertension 100 (50)  98 (50)
Asthma  27 (14)  22 (11)
Clinical status on the 7-point ordinal scale — no. (%)§
2: Receiving invasive mechanical ventilation or ECMO  4 (2)  9 (5)
3: Receiving noninvasive ventilation or high-flow oxygen  49 (24)  60 (30)
4: Receiving low-flow supplemental oxygen 113 (56) 107 (54)
5: Not receiving supplemental oxygen but requiring medical care  34 (17)  21 (11)
Median duration of hospitalization before first dose of remdesivir (IQR)  
— days
2 (1–3) 2 (1–3)
Median duration of symptoms before first dose of remdesivir (IQR) — days 8 (5–11) 9 (6–12)
Median AST level (IQR) — U/liter¶ 41 (29–58) 46 (34–67)
Median ALT level (IQR) — U/liter 32 (22–50) 36 (23–58)
Median creatinine clearance by Cockcroft–Gault (IQR) — ml/min 106 (80–142) 103 (80–140)
*  Percentages may not total 100 because of rounding. ALT denotes alanine aminotransferase, AST aspartate aminotrans-
ferase, and IQR interquartile range.
†  Race was reported by the patients.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  P = 0.02 for the comparison between the 5-day group and the 10-day group by the Wilcoxon rank-sum test.
¶  P = 0.008 for the comparison between the 5-day group and the 10-day group by the Wilcoxon rank-sum test.
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Clinical status at day 14 on the 7-point ordinal scale — no. of patients 
(%)
P = 0.14†
1: Death 16 (8)  21 (11)
2: Hospitalized, receiving invasive mechanical ventilation or ECMO 16 (8)  33 (17)
3: Hospitalized, receiving noninvasive ventilation or high-flow oxygen  9 (4) 10 (5)
4: Hospitalized, requiring low-flow supplemental oxygen  19 (10) 14 (7)
5: Hospitalized, not receiving supplemental oxygen but requiring 
 ongoing medical care
11 (6) 13 (7)
6: Hospitalized, not requiring supplemental oxygen or ongoing 
 medical care
 9 (4)  3 (2)
7: Not hospitalized 120 (60) 103 (52)
Time to clinical improvement (median day of 50% cumulative 
 incidence‡)
10 11  0.79 (0.61 to 1.01)
Clinical improvement — no. of patients (%)
Day 5  33 (16)  29 (15) 0.2% (−7.0 to 7.5)
Day 7  71 (36)  54 (27) −5.0% (−14.0 to 4.0)
Day 11 116 (58)  97 (49) −4.8% (−14.1 to 4.6)
Day 14 129 (64) 107 (54) −6.5% (−15.7 to 2.8)
Time to recovery (median day of 50% cumulative incidence‡) 10 11   0.81 (0.64 to 1.04)
Recovery — no. of patients (%)
Day 5  32 (16)  27 (14) 0.1% (−7.0 to 7.1)
Day 7  71 (36)  51 (26) −6.0% (−14.8 to 2.7)
Day 11 115 (58)  97 (49) −3.7% (−12.8 to 5.5)
Day 14 129 (64) 106 (54) −6.3% (−15.4 to 2.8)
Time to modified recovery (median day of 50% cumulative incidence‡) 9 10   0.82 (0.64 to 1.04)
Modified recovery — no. of patients (%)
Day 5  51 (26)  41 (21) −2.3% (−10.5 to 5.9)
Day 7  84 (42)  69 (35) −3.4% (−12.6 to 5.8)
Day 11 128 (64) 106 (54) −5.7% (−14.6 to 3.2)
Day 14 140 (70) 116 (59) −6.7% (−15.3 to 1.9)
*  Differences are expressed as rate differences, except in the case of time to clinical improvement, time to recovery, and time to modified 
recovery, for which differences are expressed as hazard ratios; for these time-to-event end points, the hazard ratio and its 95% confidence 
interval were estimated from a cause-specific proportional-hazards model including treatment and baseline clinical status as covariates. For 
events at prespecified time points (e.g., days 5, 7, 11, and 14), the difference in the proportion of subjects with an event under evaluation 
between treatment groups and the 95% confidence interval were estimated from the Mantel–Haenszel proportions adjusted according to 
baseline clinical status.
†  The P value was calculated from a Wilcoxon rank-sum test stratified by baseline clinical status.
‡  Clinical improvement was defined as an improvement of at least 2 points from baseline on the 7-point ordinal scale; recovery was defined 
as an improvement from a baseline score of 2 to 5 to a score of 6 or 7; and modified recovery was defined as an improvement from a base-
line score of 2 to 4 to a score of 5 to 7 or from a score of 5 to a score of 6 or 7. Cumulative incidence functions were calculated for each 
treatment group for days to the event under evaluation (i.e., clinical improvement, recovery, or modified recovery), with death as the com-
peting risk. Data for patients not achieving the event under evaluation at the last assessment were censored on the day of the last clinical 
assessment. Patients who died before achieving the event under evaluation were considered to have experienced a competing event.
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the two treatment groups despite their receiving 
the same therapy (Table S5). After adjustment 
for baseline clinical status, only serious adverse 
events were different between the two groups 
(Table S6). The most common serious adverse 
events that were more common in the 10-day 
group were acute respiratory failure (9%, vs. 
5%) and respiratory failure (5%, vs. 2%).
Laboratory abnormalities of grade 3 or higher 
occurred among 27% of patients in the 5-day 
group and 34% of patients in the 10-day group 
(Table 3). Most abnormalities were transient, with 
no significant difference between the median 
changes in the two groups at day 14. Grade 4 
creatinine clearance reductions were reported in 
12% of patients in the 10-day group, as com-
pared with 3% in the 5-day group. Most of these 
patients (71%) had been receiving either invasive 
mechanical ventilation or noninvasive positive 
pressure ventilation or high-flow nasal cannula 
at baseline, consistent with the observation that 
disease severity at baseline was associated with 
safety outcomes.
Discussion
In this open-label, randomized, multicenter, 
phase 3 trial among patients with severe Covid-19 
pneumonia due to infection with SARS-CoV-2, 
we did not find a significant difference in effi-
cacy between 5-day and 10-day courses of rem-
desivir. After adjustment for baseline imbalances 
in disease severity, outcomes were similar as mea-
sured by a number of end points: clinical status at 
day 14, time to clinical improvement, recovery, 
and death from any cause. However, these results 
cannot be extrapolated to critically ill patients 
receiving mechanical ventilation, given that few 
of the patients in our trial were receiving me-
chanical ventilation before beginning treatment 
with remdesivir.
The apparent trend toward better outcomes in 
patients treated with remdesivir for 5 days than 
in those treated for 10 days may have several 
causes. The 10-day group included a significantly 
higher percentage of patients in the most severe 
disease categories — those requiring invasive 
Figure 2. Oxygen Support on Day 14 According to Oxygen Support on Day 5.
Shown is the distribution of oxygen-support status on day 14 for the 5-day and 10-day treatment groups according 
to oxygen-support status at day 5 of therapy. Percentages are based on patients with both day 5 and day 14 oxygen-
support data available and exclude those with missing oxygen-support data for day 14. Oxygen-support status is de-
rived from the clinical status according to the seven-point ordinal scale, as follows: 1, death; 2, receiving invasive 
mechanical ventilation; 3, receiving high-flow oxygen; 4, receiving low-flow oxygen; 5 or 6, breathing ambient air; 
and 7, discharge. Data on high-flow oxygen were missing for 1 patient in the 10-day group; data on low-flow oxygen 
were missing for 3 patients in the 5-day group and 6 patients in the 10-day group, and data on ambient air were 
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Any adverse event — no. of patients (%) 141 (70) 145 (74)
Nausea  20 (10) 17 (9)
Acute respiratory failure 12 (6)  21 (11)
Alanine aminotransferase increased 11 (6) 15 (8)
Constipation 13 (6) 13 (7)
Aspartate aminotransferase increased 10 (5) 13 (7)
Hypokalemia 10 (5) 12 (6)
Hypotension  9 (4) 12 (6)
Respiratory failure  7 (4) 14 (7)
Insomnia 10 (5) 11 (6)
Acute kidney injury  4 (2) 15 (8)
Adverse event leading to discontinuation of treatment  
— no. of patients (%)
 9 (4)  20 (10)
Any serious adverse event  42 (21)  68 (35)
Acute respiratory failure 10 (5) 18 (9)
Respiratory failure  5 (2) 10 (5)
Septic shock  2 (1)  5 (3)
Acute respiratory distress syndrome   1 (<1)  5 (3)
Hypoxia  2 (1)  4 (2)
Respiratory distress  3 (2)  4 (2)
Dyspnea  4 (2)  1 (1)
Pneumothorax  2 (1)  3 (2)
Viral pneumonia  3 (2)  2 (1)
Aminotransferase levels increased  3 (2)  2 (1)
Any grade ≥3 laboratory abnormality — no. of patients/total no. (%) 53/195 (27) 64/191 (34)
Selected grade ≥3 laboratory abnormalities — no. of patients/ 
total no. (%)
Creatinine clearance decreased
Grade 3 13/193 (7) 13/188 (7)
Grade 4  5/193 (3)  23/198 (12)
ALT elevation
Grade 3  8/194 (4) 11/191 (6)
Grade 4  4/194 (2)  5/191 (3)
AST elevation
Grade 3 11/194 (6)  7/190 (4)
Grade 4  3/194 (2)  4/190 (2)
Bilirubin increased
Grade 3  1/193 (1)  3/190 (2)
Grade 4 0  1/190 (1)
*  Adverse events listed are those that occurred in at least 5% of patients in either treatment group, and serious adverse 
events listed are those that occurred in 5 or more patients.
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mechanical ventilation and high-flow oxygen — 
and a higher proportion of men (68%, vs. 60%), 
who are known to have worse outcomes with 
Covid-19.7 Although eligibility criteria excluded 
patients receiving invasive mechanical ventilation, 
13 patients who were enrolled in the trial were 
intubated before the start of treatment with rem-
desivir or were categorized as having protocol 
deviations at enrollment. Of these 13 patients, 
9 were assigned to the 10-day group, whereas 
only 4 were assigned to the 5-day group. Although 
the results could suggest that longer treatment 
with remdesivir may be detrimental, we note that 
the trend toward improved outcomes in the 5-day 
group was already evident at day 5 of the trial — 
when both groups had received the same amount 
of treatment — which suggests that differences 
between the groups were not due to treatment 
duration but to observed imbalances in baseline 
characteristics between the two groups.
Because our trial lacked a placebo control, it 
is not a test of the efficacy of remdesivir. Results 
from two clinical trials of remdesivir in patients 
with severe Covid-19 have been reported. Wang 
and colleagues conducted a randomized, double-
blind, placebo-controlled trial at 10 hospitals in 
Hubei, China.21 However, owing to a decline in 
the incidence of Covid-19 in China, enrollment 
was only about half of the planned number of 
patients, with the result that the trial was not 
powered to show a statistical difference between 
the remdesivir and placebo groups.22 Prelimi-
nary results from an ongoing randomized clini-
cal trial conducted by the National Institute of 
Allergy and Infectious Diseases showed that 10 
days of treatment with remdesivir was statisti-
cally superior to placebo for the primary end 
point, time to recovery.23 Our trial suggests that 
if remdesivir truly is an active agent, supplies 
that are likely to be limited can be conserved 
with shorter durations of therapy.
Transient elevations in liver enzymes have 
been observed after treatment with remdesivir in 
phase 1 studies among healthy volunteers, and 
preclinical studies revealed renal toxicity at expo-
sures higher than those in humans. In our trial, 
2.5% and 3.6% of patients in the 5-day and 10-day 
groups, respectively, discontinued treatment ow-
ing to aminotransferase elevations. Covid-19 itself 
has been found to be associated with liver inju-
ry.24 Patients in the 10-day group had more ele-
vations in creatinine of grade 3 or higher and 
more declines in creatinine clearance than those 
in the 5-day group. The higher frequency of grade 
4 decreases in creatinine clearance observed in 
the 10-day group may have been driven by the 
more severe disease status in that group, given 
that Covid-19 is associated with renal injury. 
Further studies will be needed to delineate the 
contribution of drug toxicity or the effects of the 
virus to these findings. Close monitoring of he-
patic and renal tests is appropriate among patients 
who are severely ill.
The interpretation of these results is limited 
by the lack of a randomized placebo control 
group and the open-label design. We designed 
this as an open-label trial for two reasons: the 
available supply of matched placebo vials had been 
allocated to other ongoing randomized, controlled 
clinical trials,21,23 and, more important, given the 
stretched health care resources during the pan-
demic, it seemed appropriate to allow for patients 
to be discharged from the hospital as soon as 
medically indicated, regardless of whether they 
had completed the full assigned course of treat-
ment with remdesivir. As a result, only 44% of 
patients in the 10-day treatment group completed 
the full course of therapy. Patients who were not 
discharged were presumably those with more 
severe illness, which may account for the different 
rates of adverse events seen in the two groups. 
Another important limitation is that we do not 
have SARS-CoV-2 viral-load results during and after 
treatment, owing to the variability in local access 
to testing and practices across the global sites.
Our trial did not show a significant differ-
ence in efficacy between a 5-day course and a 
10-day course of intravenous remdesivir treat-
ment in patients with severe Covid-19 due to 
SARS-CoV-2 who did not require mechanical 
ventilation at baseline. Patients who progress to 
mechanical ventilation may benefit from 10 days 
of remdesivir treatment; further evaluation of 
this subgroup and of other high-risk groups, 
such as immunocompromised persons, is need-
ed to determine the shortest effective duration 
of therapy.
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